Pneumococcal Infection clinical trials

Explore recruiting pneumococcal infection clinical trials.

Recruiting pneumococcal infection studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pneumococcal Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease.

Sweden, Poland, France, Finland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pneumococcal booster vaccine responsiveness to PCV20 in persons of 78-84 years of age

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Pneumococcal Infection trials by city

Pneumococcal Infection clinical trials

Recruiting pneumococcal infection studies right now

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

Serum Collection Study for Assay Development

Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Also recruiting in Europe

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease.

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

Pneumococcal booster vaccine responsiveness to PCV20 in persons of 78-84 years of age

Pneumococcal Infection trials by city

Other conditions